AIMS: The standard treatment of neonatal group B Streptococcus infection is intravenous amoxicillin for 10 days. We investigated whether effective serum amoxicillin concentrations could be reached by switching to oral amoxicillin after 48 h of intravenous administration in full-term neonates with group B Streptococcus infection. METHODS: Over 2 years, we included 222 full-term neonates who had early onset group B streptococcal disease responsive to 48 h of intravenous amoxicillin, at which point they were asymptomatic and fed orally. They were switched to oral amoxicillin (300 or 200 mg/kg per day in four divided doses). Steady-state serum amoxicillin concentrations were determined 48 h later by high-performance liquid chromatography; values > or =5 mg/l were considered effective. RESULTS: Mean gestational age was 39.32 +/- 1.5 weeks ,and mean birth weight was 3,422 +/- 533 g; 29 newborns were bacteremic. Median serum amoxicillin concentration on oral therapy was 31,.15 (range 11-118) and 25.80 (range 5-84.8) with 300 and 200 mg/kg per day, respectively. None of the infants had a concentration <5 mg/l (p < 0.001). Gastrointestinal tolerance was satisfactory; 216 patients were discharged at 5 days of age, and none was readmitted within the 3-month follow-up. CONCLUSION: Early switching to the oral route in asymptomatic full-term newborns with early onset group B streptococcal disease maintained serum amoxicillin concentrations within our predefined therapeutic range (error risk<0.001). This strategy may hold potential for reducing treatment invasiveness and shortening hospital length of stay.
AIMS: The standard treatment of neonatal group B Streptococcus infection is intravenous amoxicillin for 10 days. We investigated whether effective serum amoxicillin concentrations could be reached by switching to oral amoxicillin after 48 h of intravenous administration in full-term neonates with group B Streptococcus infection. METHODS: Over 2 years, we included 222 full-term neonates who had early onset group B streptococcal disease responsive to 48 h of intravenous amoxicillin, at which point they were asymptomatic and fed orally. They were switched to oral amoxicillin (300 or 200 mg/kg per day in four divided doses). Steady-state serum amoxicillin concentrations were determined 48 h later by high-performance liquid chromatography; values > or =5 mg/l were considered effective. RESULTS: Mean gestational age was 39.32 +/- 1.5 weeks ,and mean birth weight was 3,422 +/- 533 g; 29 newborns were bacteremic. Median serum amoxicillin concentration on oral therapy was 31,.15 (range 11-118) and 25.80 (range 5-84.8) with 300 and 200 mg/kg per day, respectively. None of the infants had a concentration <5 mg/l (p < 0.001). Gastrointestinal tolerance was satisfactory; 216 patients were discharged at 5 days of age, and none was readmitted within the 3-month follow-up. CONCLUSION: Early switching to the oral route in asymptomatic full-term newborns with early onset group B streptococcal disease maintained serum amoxicillin concentrations within our predefined therapeutic range (error risk<0.001). This strategy may hold potential for reducing treatment invasiveness and shortening hospital length of stay.
Authors: F Sevinç; J M Prins; R P Koopmans; P N Langendijk; P M Bossuyt; J Dankert; P Speelman Journal: J Antimicrob Chemother Date: 1999-04 Impact factor: 5.790
Authors: John Penders; Carel Thijs; Cornelis Vink; Foekje F Stelma; Bianca Snijders; Ischa Kummeling; Piet A van den Brandt; Ellen E Stobberingh Journal: Pediatrics Date: 2006-08 Impact factor: 7.124
Authors: Sanyukta Desai; Paul L Aronson; Veronika Shabanova; Mark I Neuman; Frances Balamuth; Christopher M Pruitt; Adrienne G DePorre; Lise E Nigrovic; Sahar N Rooholamini; Marie E Wang; Richard D Marble; Derek J Williams; Laura Sartori; Rianna C Leazer; Christine Mitchell; Samir S Shah Journal: Pediatrics Date: 2019-08-20 Impact factor: 7.124
Authors: Jillian M Cotter; Matt Hall; Sonya Tang Girdwood; John R Stephens; Jessica L Markham; James C Gay; Samir S Shah Journal: J Hosp Med Date: 2021-02 Impact factor: 2.960
Authors: Fleur M Keij; René F Kornelisse; Nico G Hartwig; Katya Mauff; Marten J Poley; Karel Allegaert; Irwin K M Reiss; Gerdien A Tramper-Stranders Journal: BMJ Open Date: 2019-07-09 Impact factor: 2.692
Authors: Fleur M Keij; René F Kornelisse; Nico G Hartwig; Irwin K M Reiss; Karel Allegaert; Gerdien A Tramper-Stranders Journal: J Antimicrob Chemother Date: 2019-11-01 Impact factor: 5.790
Authors: Abdullah H Baqui; Samir Kumar Saha; A S M Nawshad Uddin Ahmed; Mohammad Shahidullah; Iftekhar Quasem; Daniel E Roth; Emma K Williams; Dipak Mitra; A K M Shamsuzzaman; Wazir Ahmed; Luke C Mullany; Simon Cousens; Stephen Wall; Neal Brandes; Robert E Black Journal: Pediatr Infect Dis J Date: 2013-09 Impact factor: 2.129
Authors: Anita K M Zaidi; Abdullah H Baqui; Shamim Ahmad Qazi; Rajiv Bahl; Samir Saha; Adejumoke I Ayede; Ebunoluwa A Adejuyigbe; Cyril Engmann; Fabian Esamai; Antoinette Kitoto Tshefu; Robinson D Wammanda; Adegoke G Falade; Adetanwa Odebiyi; Peter Gisore; Adrien Lokangaka Longombe; William N Ogala; Shiyam Sundar Tikmani; A S M Nawshad Uddin Ahmed; Steve Wall; Neal Brandes; Daniel E Roth; Gary L Darmstadt Journal: Pediatr Infect Dis J Date: 2013-09 Impact factor: 2.129